BackJanux Therapeutics Overview

Janux Therapeutics Receivables

Janux Therapeutics's receivables is $35M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$35.00M

Peer average

Loading

Janux Therapeutics Receivables History

Loading

Janux Therapeutics vs. peers: Receivables Comparison

Loading

Janux Therapeutics Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Janux Therapeutics (JANX) FAQ

Janux Therapeutics (JANX) currently reports a receivables of $35M as of March 2026. In the prior-year period, the figure was $0. Use the charts on this page to explore Janux Therapeutics's receivables history and peer comparisons.

Janux Therapeutics's receivables changed from $0 to $35M (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Janux Therapeutics reported $35M in receivables as of March 2026. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $35M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Janux Therapeutics, and consider following JANX for alerts when major investors trade the stock.

Janux Therapeutics is classified in the Healthcare sector. On receivables, it currently shows $35M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing JANX with unrelated industries.